Current Report Filing (8-k)
February 20 2014 - 3:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange
Act of 1934
Date of Report (Date of
earliest event reported): February 20, 2014
VANTAGE HEALTH
(Exact name of registrant
as specified in its charter)
Nevada |
|
333-168930 |
|
93-0659770 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
401 Warren St. Suite
200
Redwood City, CA 94063
(Address of principal executive
offices and zip code)
Registrant’s telephone
number, including area code: (650) 503-3570
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 |
|
Entry Into a Material Definitive Agreement |
As disclosed in our Current
Report on Form 8-K filed with the Securities and Exchange Commission on January 7, 2014, our parent company, Nanobeak Inc. (“Nanobeak”),
has entered into a License Agreement (the “License Agreement”) with the National Aeronautics and Space Administration
(“NASA”) pursuant to which Nanobeak was granted a royalty-bearing, non-transferable license to certain inventions and
patent rights owned by NASA relating to chemical sensing nanotechnology for use within the United States and its territories.
Pursuant to Section 3.1.1
of the License Agreement, Nanobeak is permitted to sublicense its rights under the License Agreement to Vantage Health. Effective
as of February 20, 2014, Nanobeak has sublicensed such rights to Vantage Health as set forth in a Sublicense Agreement (the “Sublicense
Agreement”).
The Sublicense Agreement
grants patent rights to Vantage Health on the same terms as such rights have been granted to Nanobeak under the License Agreement;
provided, however, that the field of use for the patent rights granted to Vantage Health is limited to disease detection.
Vantage must pay to Nanobeak
certain royalties in connection with the Sublicense Agreement, which royalties are equivalent to those owed by Nanobeak to NASA
pursuant to the License Agreement. Vantage must further comply with other obligations of Nanobeak under the License Agreement as
though Vantage were a party thereto, including achievement of practical application of the patent rights and certain reporting
obligations.
The Sublicense Agreement
will terminate upon the earlier of (i) termination of the License Agreement or (ii) termination by either party to the Sublicense
Agreement as set forth therein.
The foregoing description
of the Sublicense Agreement is not complete and is subject to, and qualified in its entirety by, the full text of the Sublicense
Agreement, which is attached as Exhibit 10.1 hereto, the terms of which are incorporated herein by reference.
Item 9.01 Financial Statements
and Exhibits
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
VANTAGE HEALTH |
|
|
|
By: |
/s/ Jeremy Barbera |
|
Name: |
Jeremy Barbera |
|
Title: |
President and Chief Executive Officer |
Date: February 20, 2014 |
|
|
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nano Mobile Healthcare (PK) (USOTC:VNTH)
Historical Stock Chart
From Jul 2023 to Jul 2024